Lipid-lowering therapy is effective in reducing cardiovascular mortality and morbidity in people with PAD .
It may also improve local symptoms .
Until further evidence on the relative effectiveness of different lipid-lowering agents is available , use of a statin in people with PAD and a blood cholesterol level > /=3.5 mmol/litre is most indicated
BACKGROUND Lipid-lowering therapy is recommended for secondary prevention in people with coronary artery disease .
It may also reduce cardiovascular events and /or local disease progression in people with lower limb peripheral arterial disease ( PAD ) .
OBJECTIVES To assess the effects of lipid-lowering therapy on all-cause mortality , cardiovascular events and local disease progression in patients with PAD of the lower limb .
Efficacy and safety of cerivastatin and pravastatin in the treatment of primary hypercholesterolemia.
In this r and omized , double-blind , parallel group study , the efficacy and safety of cerivastatin ( 0.3 mg ) and pravastatin ( 20 mg ) were compared in 402 patients with primary hypercholesterolemia with and without documented coronary heart disease or peripheral vascular disease . After 8 weeks of treatment , cerivastatin provided significantly greater reductions than pravastatin in low-density lipoprotein (LDL)-cholesterol ( 31.1 % vs. 26.0 % ; p < 0.0001 ) and total cholesterol ( 21.1 % vs. 17.8 % ; p < 0.0001 ) . A greater proportion of patients treated with cerivastatin than pravastatin achieved > 30 % and > 40 % reductions from baseline in LDL-cholesterol . Both agents also increased high density lipoprotein-cholesterol and reduced triglycerides . Overall , 65.1 % of patients treated with cerivastatin and 63.3 % of patients with pravastatin achieved LDL-cholesterol goals defined by the National Cholesterol Education Program . Both drugs were well tolerated , with most adverse events being mild . These results demonstrate that cerivastatin ( 0.3 mg ) is a highly effective 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor , which enables a large proportion of patients to achieve clinical ly meaningful reductions in LDL-cholesterol
Lipid-lowering therapy is effective in reducing cardiovascular mortality and morbidity in people with PAD .
It may also improve local symptoms .
Until further evidence on the relative effectiveness of different lipid-lowering agents is available , use of a statin in people with PAD and a blood cholesterol level > /=3.5 mmol/litre is most indicated
BACKGROUND Lipid-lowering therapy is recommended for secondary prevention in people with coronary artery disease .
It may also reduce cardiovascular events and /or local disease progression in people with lower limb peripheral arterial disease ( PAD ) .
OBJECTIVES To assess the effects of lipid-lowering therapy on all-cause mortality , cardiovascular events and local disease progression in patients with PAD of the lower limb .